FEIBA: A Prohemostatic Agent

被引：18

作者：

Cromwell, Caroline ^{[1
]}

Aledort, Louis M. ^{[1
]}

机构：

[1] Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA

来源：

SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2012年 / 38卷 / 03期

关键词：

inhibitors; hemophilia; factor eight inhibitor bypassing activity; thrombosis; FACTOR-VIII-INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATE; THROMBIN GENERATION TEST; FACTOR-IX INHIBITORS; BYPASSING AGENTS; HEMOPHILIA-A; MYOCARDIAL-INFARCTION; PATIENT; SURGERY; SAFETY;

D O I：

10.1055/s-0032-1309286

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Factor eight inhibitor bypassing activity (FEIBA), Anti-Inhibitor Coagulation Complex has been used for over 30 years in hemophiliac patients with inhibitors. The history of its use is reviewed here, including issues related to thrombosis, efficacy, and comparison to alternative bypassing agents. The need for surrogate assays to monitor effective hemostasis with the use of FEIBA remains.

引用

页码：265 / 267

页数：3

共 24 条

[1] MedWatch: an important instrument for postlicensing surveillance [J].

Aledort, L. M. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (07) :1637-1637

[2] A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study [J].

Astermark, Jan ;

Donfield, Sharyne M. ;

DiMichele, Donna M. ;

Gringeri, Alessandro ;

Gilbert, Steven A. ;

Waters, Jennifer ;

Berntorp, Erik .

BLOOD, 2007, 109 (02) :546-551

[3] Inhibitor treatment in haemophillas A and B: Summary statement for the 2006 International Consensus Conference [J].

Berntorp, E. ;

Shapiro, A. ;

Astermark, J. ;

Blanchette, V. S. ;

Collins, P. W. ;

Dimichele, D. ;

Escuriola, C. ;

Hay, C. R. M. ;

Hoots, W. K. ;

Leissinger, C. A. ;

Negrier, C. ;

Oldenburg, J. ;

Peerlinck, K. ;

Reding, M. T. ;

Hart, C. .

HAEMOPHILIA, 2006, 12 :1-7

[4] Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors [J].

Berntorp, E. .

HAEMOPHILIA, 2009, 15 (01) :3-10

[5] INTRAVASCULAR COAGULATION WITH USE OF HUMAN PROTHROMBIN COMPLEX CONCENTRATES [J].

CEDERBAUM, AI ;

BLATT, PM ;

ROBERTS, HR .

ANNALS OF INTERNAL MEDICINE, 1976, 84 (06) :683-687

[6]

CHAVIN S I, 1988, American Journal of Medicine, V85, P245, DOI 10.1016/S0002-9343(88)80353-X

[7] The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99 [J].

Darby, SC ;

Keeling, DM ;

Spooner, RJD ;

Kan, SW ;

Giangrande, PLF ;

Collins, PW ;

Hill, FGH ;

Hay, CRM .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (07) :1047-1054

[8] Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision [J].

Dargaud, Y ;

Lienhart, A ;

Meunier, S ;

Hequet, O ;

Chavanne, H ;

Chamouard, V ;

Marin, S ;

Negrier, C .

HAEMOPHILIA, 2005, 11 (05) :552-558

[9] Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery [J].

Dargaud, Yesim ;

Lienhart, Anne ;

Negrier, Claude .

BLOOD, 2010, 116 (25) :5734-5737

[10] A retrospective postlicensure survey of FEIBA efficacy and safety [J].

DiMichele, D. ;

Negrier, C. .

HAEMOPHILIA, 2006, 12 (04) :352-362

← 1 2 3 →